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INTRODUCTION 
FK 506 was discovered in 1984 in Japan and the first 
reports on its in vitro and in vivo immunosuppressive 
properties were published in 1987 (1-6). The clinical use 
of FK 506 in solid organ transplantation began in March 
1989, when a clinical trial in liver transplantation was 
started at the University of Pittsburgh. Initially, the new 
drug was used to "rescue" rejecting liver allografts under 
cyclosporine based immunosuppression (7,8). A few months 
later the use of FK 506 was extended to primary 
immunosuppressive treatment for transplantation of the liver 
and subsequently of the kidneys and the thoracic organs 
(9,10). 
We will summarize here the results previously reported 
on the initial clinical experience and the properties of FK 
506. 
PHARMACOKINETIC PROPERTIES OF FK 506 
FK 506 is a macrolide antibiotic which is many times 
more potent than cyclosporine on a weight basis. The 
molecular structure of FK 506 is unrelated to that of 
cyclosporine and the two drugs have different cytosolic 
binding sites (11,12). However both drugs inhibits T-
lymphocyte activation and suppress the synthesis and 
expression of multiple cytokines such as interleukin 2 and 
gamma-interferon (1,3,6). 
FK 506 is incompletely absorbed after oral 
administration and its distribution in the body is 
extensive. The time required to reach peak concentration 
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varies from 1 to 4 hours. FK 506 is a high clearance drug, 
which is completely metabolized by the liver so that less 
than 1% of the dose is excreted unmetabolized in the urine. 
The mean half-life is 8.7 hours (13). 
Changes in FK 506 dosage do not seem to be necessary in 
patients with kidney failure or in patients on dialysis. 
However, with hepatic dysfunction accumulation of FK 506 may 
be rapid unless dose reductions are made promptly (14,15). 
LIVER TRANSPLANTATION: "RESCUE" 
A group of 121 liver allograft recipients with 
cyclosporine related complications (resistant cellular 
rejection, nephrotoxicity, hypertension, excessive steroid 
toxicity) was converted to FK 506 immunosuppression (8,16). 
In the majority of these patients, the oral FK 506 treatment 
was started (0.3 mg/Kg/day divided in two doses) 12-24 hours 
after cyclosporine treatment had been stopped. In a smaller 
group of patients, the initial doses of FK 506 were given 
intravenously (0.15 mg/kg/day) in order to treat a severe 
acute cellular rejection resistant to the conventional 
therapy. 
After a follow-up period ranging from 1 to 12 months 
(median time 95 days), 101 patients were alive with normal 
liver function, 6 patients required retransplantation 
because of progressive liver dysfunction and 14 died. Sepsis 
represented the primary cause of death (7 cases). However, 
6 of these patients were septic at the time of the 
conversion. The other patients died because of primary non-
function of the liver allograft (2), fulminant B virus 
hepatitis (1), metastatic hepatoma (1), liver failure-
chronic rejection (1), rupture of splenic artery aneurysm 
(1) or intraoperative death (1). 
Liver function improved in most patients: the median 
total bilirubin was 3.8 mgjdl at the time of conversion and 
fell to 1.4 mg/dl 1 month and later after the initiation of 
FK 506. Similar findings were noted with the median SGOT, 
which improved from 291 IU/l to 96 IU/l in the same period 
of time. 
The benefit of FK 506 conversion was surprising in a 
highly selected group of patients, with end stage liver 
disease (defined by a serum bilirubin >2.5 mg/dl) and with 
chronic rejection documented by histology. In this group the 
median time of FK 506 conversion was 17 months following 
transplantation. Six patients required retransplantation for 
persistent liver failure, while the remaining 13 had both 
histological and clinical improvement. 
Steroid doses were eliminated or reduced in over 50% of 
FK 506 converted patients, allowing reversal of the steroid 
morbidity. 
PRIMARY LIVER TRANSPLANTATION 
Of the 120 patients enrolled in this group, 105 were 
adults and 15 were children (9). Non-alcoholic and alcoholic 
cirrhosis accounted for two thirds of the adult indications. 
Primary biliary cirrhosis and sclerosing cholangitis were 
the indications in only 27% of the patients. In 8 of the 15 
pediatric patients, biliary atresia was the indication for 
the transplant, followed by cirrhosis (4), tumor (2) and 
fulminant failure (1). 
The immunosuppression with FK 506 was started in the 
operating room with an intravenous dose of 0.075 mg/kg 
infused over 4 hours and repeated every 12 hours until the 
oral intake was began. We now believe that this induction 
dose should be 0.10 mg/kg in the first day, given as a 
constant infusion over the 24 hour span instead of in 
boluses. An oral dose of 0.15 mg/kg every 12 hours was 
started when the patient could eat. Dose adjustments were 
dictated by plasma trough levels, quality of the graft 
function, toxicity symptoms. 
All of the patients were given steroids. The first 50% 
received 1 g. intravenous methylprednisolone after graft 
reperfusion followed by a rapid daily taper from 200 mg to 
20 mg. over 5 days. In the second half of the series, the 
intraoperative bolus and subsequent steroid cycle were 
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Figure 1 --- Life survival curves for primary liver 
transplant recipients given FK 506 and cyclosporine. The 
upper curve is for 125 liver transplant patients, the middle 
curve is for the 110 adult patients, while the bottom curve 
is the for the 15 pediatric patients, under the age of 18. 
Adapted from Todo et ai, Ann Surg 212:295-305, 1990. 
omitted, using 20 mg/day from the outset. The pediatric 
doses of steroids were adjusted downwards according to 
patient size. 
After a follow-up period of 2 to 7.5 months, 112 of the 
120 patients (93.3%) were alive (fig.1). Only 7 patients 
required retransplantation (5.8%) and the only graft lost 
for rejection was in a highly sensitized patient with 
positive antidonor cytotoxic cross-matches. Sepsis was the 
primary cause of death (4 cases); 3 patients died of 
technical complications and one child with fulminant hepatic 
failure died of coma after the liver transplant. 
The function of the grafts in the surviving patients 
was good. The median bilirubin was 0.5 mg/dl and only one 
patient with recently repaired duct obstruction had a 
bilirubin over 2 mg/dl. The median SGOT and alkaline 
phosphatase were in a normal range: 50 IU/L and 153 IU/L 
respectively. The median creatinine was 1.4 mg%. 
The requirement of steroids was low. A rapid dose 
reduction of steroids was attempted during the first month 
so that by the second and the third month the daily average 
doses were less then 5 mg/d. When compared to a historical 
control group of 400 patients treated with cyclosporine 
based immunosuppression, the use of additional 
immunosuppression for the treatment of rejection in the FK 
506 patients was significantly less. The absolute rate of 
clinical rejection was less (p<0.01) and the episodes were 
much easier to reverse (9). FK 506 treated patients required 
only 43% of the steroid boluses used in the cyclosporine 
controls, 7% of the steroid recycles, 4% azathioprine use, 
and 23% of the OKT3 courses used to treat rejection. 
While the infectious disease profiles were similar when 
compared to the historical control, the incidence of 
bacterial and fungal infections have been reduced. The most 
common viral infection was cytomegalovirus (17). Two 
patients developed symptomatic EBV infection which was 
confirmed histologically and were associated to a 
polyclonal lymphoproliferative disease. 
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The principal adverse reactions seen were 
nephrotoxicity, neurotoxic symptoms (tremors, paresthesias, 
insomnia, mood changes) and diabetogenity. The incidence of 
a new onset diabetes requiring insulin was 8.9% (9). Two 
patients developed transient expressive aphasia in the early 
postoperative period (18). 
KIDNEY AND THORACIC ORGANS 
A detailed report of the kidney cases has been reported 
elsewhere (10). In summary, 36 renal transplant recipients 
were treated with FK 506 immunosuppression. This group of 
patients represented a high risk population because their 
high sensitization and other risk factors including prior 
liver transplantation (29%), previous kidney transplantation 
(29%) and degree of illness. with a follow-up of 4 to 13 
months, all but 2 of the 36 patients were alive, 29 (81%) 
were dialysis-free and most had good renal function. The low 
steroid doses, a relatively freedom from hypertension and 
low serum cholesterol levels were noteworthy in these 
patients. Only one kidney was lost to cellular rejection and 
a high rate of irreversible humoral rejection occurred in 
patients with antidonor cytotoxic antibodies in current or 
historical serum samples (3 of 9 patients). 
The 11 heart recipient were all alive and in good 
clinical condition after a follow-up of 2 to 6 months 
(9,19). These patients had a striking freedom from 
hypertension that was common in historical controls and most 
of them had normal serum cholesterol levels. The two double-
lung and the heart-lung recipients never received 
maintenance steroid therapy and they were alive and in good 
conditions respectively after 130, 165, and 173 days. 
DISCUSSION 
The advent of cyclosporine had a fundamental impact in 
Nevertheless the development of rejection remained the most 
frequent complication, often requiring high doses of 
steroids and other drugs (azathioprine, monoclonal antibody, 
antilymphocyte globulin) to prevent or to treat rejection. 
As a consequence of this, other complications, primarily 
infectious, can occur. 
The advent of FK 506 may represent an important advance 
in immunosuppression for two reasons. First, this drug 
offers an option for patients already transplanted with 
failing grafts under cyclosporine therapy. The second reason 
is the efficacy and flexibility with which FK 506 can be 
used as primary therapy. In transplant patients treated with 
FK 506 there was a decreased incidence of rejection and of 
bacterial or fungal infections without an increased risk of 
lymphoproliferative disease or irreversible toxicity (9). 
The response of a special group of patients with 
chronic rejection was surprising, namely those with the 
"vanishing bile duct syndrome", has been considered a 
progressive and largely irreversible form of rejection. Most 
of the patients who did not respond had lost more than 50% 
of their bile ducts and had obliterative arteriopathy 
confirmed by histology. The hepatotrophic properties of FK 
506, demonstrated in experimental studies (20) might help 
explain FK 506 ability to reverse the histological damage of 
chronic rejection. 
When FK 506 was the primary treatment in liver 
transplantation, it usually could be used as monotherapy 
after perioperative induction with an FK 506-steroid 
combination. In the kidney and thoracic organs, the results 
also are encouraging, even if the number of patients is 
still small. Prospective, randomized trials comparing FK 506 
therapy with cyclosporine based immunosuppression are 
currently underway in liver and kidney transplantation. 
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